Our findings highlight the importance of environmental and societal factors as potential explanations of the observed regional disparities in COVID-19 outcomes among people with rheumatic disease and lay foundation for a new research agenda to address these disparities.
The association of female sex with certain rheumatic symptoms and diseases is now indisputable. Some of the most striking examples of this association occur in…
We read with interest the comment by Su-Ann Yeoh and colleagues1 discussing patient and public involvement in research. Both The Lancet2 and the BMJ3 have…
In people with painful hand osteoarthritis, treatment with 0·5 mg of colchicine twice day for 12 weeks did not effectively relieve pain, and treatment with…
Colchicine is an ancient drug, derived from plants of the Colchicum variety (or Autumn Crocus). Mentioned in the Ancient Egyptian Ebers papyrus, colchicine was purified…
In this large cohort study of patients with psoriasis, treatment with IL-12/23 inhibitors or IL-23 inhibitors was associated with reduced risk of progression to inflammatory…
The efficacy of baricitinib, a selective inhibitor of Janus kinase 1 and 2, in systemic lupus erythematosus (SLE) was inconclusive following two identically designed multicentre,…
Many people with rheumatic diseases participate in research, despite the burdens involved, to contribute to the wellbeing of others with rheumatic diseases, and most want…
Kimberly Templeton describes herself as having two personas, one driven by a desire to affect change and the other by her creativity. Both, however, come…
Patients with pre-existing rheumatoid arthritis initiating immune checkpoint inhibitors had similar risk of mortality and severe immune-related AEs as matched comparators. Although patients with pre-existing…
Immune checkpoint inhibitors, a class of immunotherapy, have revolutionised cancer therapy. Nearly half of all patients with metastatic cancer are eligible for immune checkpoint inhibitor…
